SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal informs about outcome of board meeting

06 May 2021 Evaluate
Hikal has informed that Board of Directors of the Company at its meeting held today i.e., May 06, 2021, considered, and approved: the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2021. The Audited Financial results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2021 are enclosed in terms of Regulation 33 of SEBI (LODR) Regulations, 2015 together with Auditor's Report and the declaration of unmodified opinion; recommendation of Final Dividend for the financial year 2020-21 on equity share capital @ 50% [Re 1 per equity share, nominal value of Rs 2 each], aggregating to dividend of 100% (Rs 2 per equity share) {including Interim Dividend of Re 1 per share (50%) paid to the shareholders in the month of March, 2021, subject to the approval of shareholders in the ensuing Annual General Meeting (AGM). Final Dividend, if approved by the shareholders at the ensuing AGM, will be paid within 30 days of the AGM date; The appointment of Jai Hiremath (DIN: 00062203) Chairman & Managing Director of the Company as Executive Chairman with effective from October 1, 2021, subject to the approval of shareholders at the ensuing Annual General Meeting; and the appointment of Sameer Hiremath (DIN: 00062129), Joint Managing Director and CEO of the Company as Managing Director of the Company with effective from October 1, 2021, subject to the approval of shareholders at the ensuing Annual General Meeting. Also informed that that the trading window for trading in securities of the Company by Designated Persons will remain closed from April 1, 2021, till the end of 48 hours from the declaration of financial results of the Company for the quarter and financial year ended March 31, 2021, the trading window will re-open on Sunday, May 9, 2021.

The above information is a part of company’s filings submitted to BSE.

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×